R. Rueger

发表

Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients

James Rosinski, Paul Delmar, J. Rosinski, 2009, Molecular Cancer Therapeutics.

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of RO5068760, an MEK Inhibitor, in Healthy Volunteers: Assessment of Target Suppression

R. Rueger, P. Goelzer, H. Niu, 2010, Journal of clinical pharmacology.

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker

S. Mu, R. Rueger, P. Goelzer, 2009, Clinical Cancer Research.

Cancer Therapy : Clinical The Safety , Tolerability , Pharmacokinetics , and Pharmacodynamics of Single Oral Doses of CH 4987655 in Healthy Volunteers : Target Suppression Using a Biomarker

S. Mu, R. Rueger, P. Goelzer, 2009 .

Loss of diphthamide pre-activates NF-κB and death receptor pathways and renders MCF7 cells hypersensitive to tumor necrosis factor

I. Pastan, U. Brinkmann, T. Racek, 2015, Proceedings of the National Academy of Sciences.

Acute myeloid leukemia patients’ clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts

Michel Theron, W. Pierceall, B. Reis, 2016, Haematologica.

Automated Brightfield Dual-Color In Situ Hybridization for Detection of Mouse Double Minute 2 Gene Amplification in Sarcomas

B. Rubin, R. Nagle, R. Tubbs, 2011, Applied immunohistochemistry & molecular morphology (Print).

Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

P. Vyas, B. Graves, M. Andreeff, 2015, Clinical Cancer Research.

First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors

F. Rojo, J. Albanell, J. Soria, 2012, Clinical Cancer Research.

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.

Jean-Yves Blay, J. Blay, L. Vassilev, 2012, The Lancet. Oncology.

Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma

M. Venturi, D. Skene, P. Workman, 2017, Molecular Cancer Therapeutics.

MDM2 antagonist clinical response association with a gene expression signature in acute myeloid leukaemia

S. W. Han, W. Pierceall, L. Essioux, 2015, British journal of haematology.

Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

J. Schellens, R. Rueger, M. Scheulen, 2012, Clinical Cancer Research.

Cancer Therapy: Clinical Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

J. Schellens, R. Rueger, M. Scheulen, 2012 .

Neoadjuvant MDM2 antagonist RG7112 for well-differentiated and dedifferentiated liposarcomas (WD/DD LPS): A pharmacodynamic (PD) biomarker study.

J. Blay, A. Italiano, A. Le Cesne, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics (PK) and pharmacodynamics (PD) of RG7112, an oral murine double minute 2 (MDM2) antagonist, in patients with leukemias and solid tumors.

L. Vassilev, M. Andreeff, R. Kurzrock, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics (PK) and pharmacodynamics (PD) of RG7112, an oral murine double minute 2 (MDM2) antagonist, in patients with leukemias and solid tumors.

L. Vassilev, M. Andreeff, R. Kurzrock, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of RO5068760, an MEK Inhibitor, in Healthy Volunteers: Assessment of Target Suppression

R. Rueger, P. Goelzer, H. Niu, 2010, Journal of clinical pharmacology.

Cancer Therapy: Clinical Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

J. Schellens, R. Rueger, M. Scheulen, 2012 .